|
|
Vaccine Detail
|
MART-1 Vaccinia Vaccine |
| Vaccine Information |
- Vaccine Name: MART-1 Vaccinia Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007504
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: MLANA
- MLANA-Dupli
gene engineering:
- Description: A cancer vaccine consisting of an attenuated recombinant vaccinia virus expressing the melanoma-associated antigen MART-1. Vaccination with this agent may stimulate cytotoxic host immune responses to melanoma cells. (NCI04) (NCIT_C2774).
|
| Host Response |
|
|
| References |
NCIT_C2774: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2774]
Schütz et al., 2001: Schütz A, Oertli D, Marti WR, Noppen C, Padovan E, Spagnoli GC, Heberer M, Zajac P. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen. Cancer gene therapy. 2001; 8(9); 655-661. [PubMed: 11593334].
|
|
